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Background:  The  United  States  is experiencing  an opioid  overdose  epidemic.  Treatment  use  data  from
diverse  racial/ethnic  groups  with  opioid  use  disorder  (OUD)  are  needed  to  inform  treatment  expansion
efforts.
Methods: We  examined  demographic  characteristics  and  behavioral  health  of  persons  aged  ≥12 years
that  met  criteria  for  past-year  OUD  (n =  6,125)  in the  2005–2013  National  Surveys  on  Drug  Use  and
Health  (N  = 503,101).  We  determined  the  prevalence  and  correlates  of  past-year  use  of  alcohol/drug  use
treatment  and  opioid-speciﬁc  treatment  to inform  efforts  for improving  OUD  treatment.
Results:  Among  persons  with  OUD,  81.93%  had  prescription  (Rx)  OUD only,  9.75%  had  heroin  use  disor-
der  (HUD)  only,  and  8.32%  had  Rx OUD  +  HUD.  Persons  with  Rx OUD  + HUD  tended  to  be white,  adults
aged  18–49,  males,  or uninsured.  The  majority  (80.09%)  of  persons  with  OUD  had  another  substance
use  disorder  (SUD),  and  major  depressive  episode  (MDE)  was common  (28.74%).  Of  persons  with  OUD,
26.19%  used  any  alcohol  or drug  use  treatment,  and  19.44%  used  opioid-speciﬁc  treatment.  Adolescents,
the  uninsured,  blacks,  native-Hawaiians/Paciﬁc-Islanders/Asian-Americans,  persons  with  Rx  OUD  only,
and persons  without  MDE  or SUD  particularly  underutilized  opioid-speciﬁc  treatment.  Among  alco-
hol/drug  use  treatment  users,  self-help  group  and  outpatient  rehabilitation  treatment  were  commonly
used  services.
Conclusions:  Most  people  with  OUD report  no  use  of OUD  treatment.  Multifaceted  interventions,  including
efforts  to  access  insurance  coverage,  are  required  to  change  attitudes  and  knowledge  towards  addic-
tion  treatment  in  order  to  develop  a supportive  culture  and infrastructure  to enable  treatment-seeking.
Outreach  efforts  could  target  adolescents,  minority  groups,  and  the  uninsured  to  improve  access  to
treatment.
© 2016  The  Author(s).  Published  by Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the CC. Introduction
The opioid (opioid analgesics/heroin) overdose epidemic is
mong the most pressing public health issues in the United States
Volkow et al., 2014). However, substantial barriers exist for per-
ons seeking medication-assisted treatment (MAT), including a
imited number of MAT  providers that treat opioid use disor-
er (OUD; Jones et al., 2015a,b). To combat this opioid epidemic,
he U.S. Department of Health and Human Services (USDHHS)
∗ Corresponding author at: Department of Psychiatry and Behavioral Sciences,
uke University School of Medicine, Duke University Medical Center, Box 3903,
urham, NC, 27710, United States.
E-mail address: litzy.wu@duke.edu (L.-T. Wu).
ttp://dx.doi.org/10.1016/j.drugalcdep.2016.10.015
376-8716/© 2016 The Author(s). Published by Elsevier Ireland Ltd. This is an open acces
c-nd/4.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
has launched an opioid initiative to supporting efforts aimed at
improving opioid prescribing practices, expanding use of nalox-
one to prevent overdoses, and extending use of MAT  to treat OUD
(Macrae et al., 2015). The USDHHS also released a new rule to
allow qualiﬁed physicians to increase the number of patients with
OUD they can treat with buprenorphine from 100 to 275 (Federal
Register, 2016). Timely population-based data about persons with
prescription (Rx) OUD or heroin use disorder (HUD) are needed
to inform federal initiatives for improving access to MAT  for pop-
ulation subgroups, including underserved racial/ethnic groups, to
reduce opioid addiction. This paper considers both Rx OUD and
HUD and focuses on unique aspects of opioid-speciﬁc treatment
use among racial/ethnic groups.
In the United States, an estimated 12.5 million people were past-
year nonmedical Rx opioid users, and an estimated 0.8 million
s article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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eople were past-year heroin users in 2015 (Center for Behav-
oral Health Statistics and Quality [CBHSQ], 2016). Past-year Rx
UD is the second most prevalent illicit or nonmedical drug use
isorder (DUD), affecting 2.0 million people aged ≥12 years; and
.6 million persons aged ≥12 years had past-year HUD in 2015
CBHSQ, 2016). The National Epidemiologic Survey on Alcohol and
elated Conditions–III (NESARC-III) indicated that lifetime preva-
ence of DSM-IV Rx OUD among adults aged ≥18 rose from 1.4% in
001–2002 to 2.9% in 2012–2013 (Saha et al., 2016). Whites and
ow-income adults had elevated odds of lifetime Rx OUD (Saha
t al., 2016). Approximately 1% of the US adolescents aged 12–17,
r 16% of adolescents that used Rx opioids nonmedically in the
ast year, had Rx OUD (Wu et al., 2008). In both adolescents and
dults, having major depression was positively associated with the
everity of Rx OUD (Wu et al., 2008, 2011a). Findings from the
reatment Episode Data Set (TEDS) indicated that the treatment
dmission rate for opioid use other than heroin was 167% higher
n 2013 (57/per 100,000 population aged ≥12 years) than the rate
n 2003 (21/per 100,000) (SAMHSA, 2015). The treatment admis-
ion rate for primary heroin use was 5% higher in 2013 (118/per
00,000 population aged ≥12 years) than the rates in 2003 (112/per
00,000) with a major increase among whites (SAMHSA, 2015).
verall, while prevalence of HUD is lower than Rx OUD nationally
CBHSQ, 2016), heroin use represented the majority (63%) of all opi-
id treatment admissions in TEDS (SAMHSA, 2015). The data reveal
he importance of characterizing Rx OUD and HUD in treatment use
esearch.
Of note, Rx opioid overdose death rates have increased pro-
ressively since around 1999 (Paulozzi, 2012). By around 2009,
rug-involved overdose death rates (mainly Rx opioids) have
assed motor vehicle trafﬁc crash mortality rates (Paulozzi, 2012).
early half a million Americans died from drug overdoses dur-
ng 2000–2014, and opioids/heroin were involved in 61% (28,647
eaths) of all drug overdose deaths in 2014 (Rudd et al., 2016).
etween 2013 and 2014, signiﬁcant increases in drug overdoses
ere found among both sexes, whites, and blacks. Heroin use also
ccounted for recent major increases in opioid overdose deaths
Rudd et al., 2016). Speciﬁcally, due to pharmacological similari-
ies, availability, or high purity of heroin, Rx opioid overdoses are
inked with a surge in heroin overdoses (Compton et al., 2016). Rx
pioid misuse/OUD was positively associated with heroin use/HUD
Jones et al., 2015a,b; Jones, 2016; Pollini et al., 2011). The odds
f problematic heroin use indicators tended to be positively asso-
iated with frequent nonmedical opioid use across racial/ethnic
roups, suggesting that all racial/ethnic groups should be a focus
f intervention efforts to reduce opioid addiction (Martins et al.,
015).
Multiple factors have contributed to this opioid overdose epi-
emic, including availability of prescription and illicit opioids,
nsafe prescribing of opioids, doctor shopping for opioids, and opi-
te diversion (Lev et al., 2016; Paulozzi, 2012). Opioid addiction is
 chronic disease that often requires MAT  for an adequate dura-
ion to facilitate recovery (Kampman and Jarvis, 2015; Volkow and
cLellan, 2016). Expanding access to MAT  and addiction services to
educe opioid overdoses and enhance recovery is a key emphasis in
he federal initiatives (Macrae et al., 2015). Nonwhite racial/ethnic
roups, which generally have lower income than whites and expe-
ience greater disparities in healthcare, are the fastest growing
opulation in the United States (Colby and Ortman, 2015). To effec-
ively combat the opioid epidemic, federal initiatives to expand
ccess to OUD treatment should reach racial/ethnic and under-
erved groups. For example, low-income or lack of insurance was
ositively associated with having Rx OUD, and Rx OUD prevalence
ad increased among low-income or uninsured people as well as
esidents of large metropolitan areas (Jones, 2016). Among non-endence 169 (2016) 117–127
medical Rx opioid users, the prevalence of heroin use had increased
among whites and Hispanics (Martins et al., 2015).
To inform interventions aimed at improving access to Rx OUD
and HUD treatment use, we utilize the national sample from the
2005–2013 National Surveys on Drug Use and Health (NSDUH)
to examine the prevalence and correlates of treatment use. We
include both Rx OUD and HUD to provide fuller information about
treatment needs for OUD. This analysis is among the ﬁrst efforts
to leverage national datasets and include both Rx OUD and HUD
in an effort to produce newer estimates for opioid-speciﬁc treat-
ment use by race/ethnicity. Among persons aged ≥12 years with
past-year OUD, we  determine their sociodemographic characteris-
tics; calculate prevalence of behavioral health indicators; examine
prevalence and correlates of past-year use of treatment for alco-
hol/drug use, drug use treatment, and opioid-speciﬁc treatment,
respectively; and explore the location of treatment received among
those accessing treatment in the past year. Given that male sex,
middle age, white race, low income, non-metropolitan residence,
other substance use disorder (SUD), and mental health problems
are all positively associate with opioid overdose deaths (Paulozzi,
2012; Rudd et al., 2016), we  examine the extent to which demo-
graphics, socioeconomic factors, and behavioral health status are
associated with receipt of treatment.
2. Methods
2.1. Data source
The NSDUH provides the primary source of national estimates of
past-year OUD among civilian, noninstitutionalized persons aged
≥12 years (SAMHSA, 2006, 2014). Its target population included
residents of households and persons in non-institutional group
quarters (shelters, boarding houses, college dormitories, migra-
tory workers’ camps, halfway houses) from 50 states and District
of Columbia. NSDUH used stratiﬁed, multistage area probability
sampling methods to select a representative sample of the U.S.
population aged ≥12 years.
NSDUH data collection included screening of the eligible house-
holds for eligible participants and the conduct of the face-to-face
household interview at the participant’s home. Computer-assisted
personal interviewing, in which interviewers read less-sensitive
questions to respondents and entered the respondents’ answers
on the laptop, was employed to collect demographic informa-
tion. Audio Computer-Assisted Self-Interviewing (ACASI), in which
respondents read or listened to the questions on headphones and
then entered their answers directly on the NSDUH laptop com-
puter, was employed to provide respondents with a private mode
for responding to questions about illicit drug use, mental health,
and other sensitive behaviors (Turner et al., 1998).
A total of 503,101 persons aged ≥12 years were included
in the public-use datasets from the 2005–2013 NSDUH
(n = 55,110–58,397/year). These surveys used similar designs
to allow analysis of the pooled sample. Weighted response rates
of household screening and interviewing for these years were
84–91% and 72–76%, respectively (SAMHSA, 2006, 2014). In
the total sample, 0.79% (unweighted n = 6,125) met  criteria for
past-year OUD (range: 0.69–0.89% in 2005–2013) that formed the
analysis sample.
2.2. Study variablesWe  used Andersen’s healthcare utilization model to organize
correlates of receipt of treatment (Andersen, 1995), which sug-
gested that receipt of substance use treatment was inﬂuenced by
persons’ predisposing or demographic (age, sex, race/ethnicity),
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Table 1
Characteristics of persons aged ≥12 years with past-year opioid use disorder: 2005–2013 NSDUH.
Race/ethnicity Total White Black Native-American Native-Hawaiian/
Paciﬁc-Islander/
Asian-American‡
Mixed-Race Hispanic
Sample size, unweighted n = 6,125 n = 4,361 n = 459 n = 141 n = 99 n = 266 n = 799
Weighted% % (SE) % 95% CI % 95% CI % 95% CI % 95% CI % 95% CI % 95% CI
Age in years
12–17 11.66 (0.47) 10.66 9.73–11.65 11.73 9.27–14.74 12.72 7.45–20.88 10.29 5.09–19.70 22.83 15.46–32.36 15.74 12.88–19.10
18–25  31.70 (1.03) 34.43 32.27–36.65 20.37 14.83–27.31 22.14 12.90–35.32 28.83 15.35–47.51 37.64 27.08–49.54 25.62 20.71–31.24
26–34  24.25 (1.01) 26.15 23.67–28.78 17.10 11.33–24.99 13.42 6.50–25.71 9.06 3.41–21.93 12.67 6.56–23.07 23.45 17.52–30.63
35–49  20.85 (1.13) 19.52 17.26–22.00 27.95 21.14–35.95 20.02 9.37–37.74 50.21 28.54–71.80 26.15 13.12–45.36 18.49 13.78–24.34
50+  11.53 (1.38) 9.25 6.68–12.68 22.85 14.61–33.89 31.70 15.48–54.05 1.61 0.21–11.43 0.71 0.16–3.06 16.71 10.37–25.79
Sex
Male  57.39 (1.13) 57.26 54.92–59.57 53.09 43.66–62.30 54.53 35.03–72.73 63.14 47.02–76.78 40.36 28.87–53.02 62.22 55.14–68.81
Female  42.61 (1.13) 42.74 40.43–45.08 46.91 37.70–56.34 45.47 27.27–64.97 36.86 23.22–52.98 59.64 46.98–71.13 37.78 31.19–44.86
Total  annual family income
<$50,000 67.12 (1.16) 62.98 60.36–65.53 83.78 77.75–88.41 88.98 81.13–93.82 58.89 41.38–74.40 71.48 58.15–81.88 76.44 70.11–81.77
$50,000–$74,999 13.50 (0.71) 14.94 13.25–16.80 6.54 3.87–10.84 6.03 2.95–11.94 19.43 9.87–34.69 8.59 4.81–14.87 11.02 7.43–16.04
$75,000+ 19.37 (0.91) 22.08 20.11–24.19 9.69 5.64–16.15 4.99 2.10–11.38 21.68 7.88–47.24 19.93 10.48–34.62 12.54 8.68–17.78
Population density
Large metropolitan 49.99 (1.04) 45.73 43.44–48.03 62.38 53.96–70.11 24.56 12.96–41.59 75.14 61.52–85.10 47.85 34.52–61.49 63.00 55.96–69.52
Small  metropolitan 43.97 (1.01) 47.72 45.51–49.93 31.21 24.35–39.01 47.97 32.27–64.09 24.86 14.90–38.48 47.89 35.02–61.04 34.78 28.42–41.74
Nonmetropolitan 6.04 (0.50) 6.56 5.59–7.68 6.41 2.07–18.12 27.46 12.00–51.26 0 . . .. . . 4.26 1.56–11.14 2.22 1.09–4.49
Health  insurance
Private 40.97 (1.13) 43.76 41.28–46.28 27.88 20.76–36.33 28.94 13.64–51.24 66.23 48.55–80.30 38.35 27.13–50.98 32.93 26.54–40.02
Public  28.98 (1.21) 25.03 22.79–27.42 49.40 39.81–59.03 51.66 35.64–67.34 21.27 8.21–44.94 41.69 28.23–56.51 33.70 27.48–40.54
None  30.05 (1.16) 31.21 28.68–33.85 22.72 16.61–30.26 19.40 9.04–36.82 12.50 5.92–24.49 19.96 11.97–31.39 33.37 27.31–40.04
Opioid  use disordera
Opioid abuse 24.73 (1.00) 20.70 18.89–22.64 31.10 23.82–39.46 21.81 12.50–35.24 46.19 27.52–65.99 20.52 12.73–31.35 39.24 32.98–45.88
Opioid  dependence 75.27 (1.00) 79.30 77.36–81.11 68.90 60.54–76.18 78.19 64.76–87.50 53.81 34.01–72.48 79.48 68.65–87.27 60.76 54.12–67.02
Rx  opioid use disorder, yes 90.08 (0.66) 91.88 90.55–93.04 82.12 75.64–87.16 95.36 86.76–98.47 98.85 94.62–99.76 85.95 65.89–95.09 84.74 78.26–89.55
Heroin  use disorder, yes 18.19 (0.90) 17.72 15.81–19.80 23.29 17.22–30.70 6.34 2.54–14.96 3.94 1.19–12.21 21.23 10.71–37.72 19.97 14.93–26.18
SE: standard error; CI: conﬁdence interval.
a Opioid use disorder included Rx opioid or heroin use disorder in the past year. ‡  Estimates are preliminary due to sample size.
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nabling (e.g., insurance, income, population density of residence),
nd severity (e.g., comorbid SUD) factors (Rosenblatt et al., 2015;
u et al., 2003, 2007).
.2.1. Demographic and enabling variables. Respondents’ self-
eported race/ethnicity, age, sex, total family income, population
ensity of residence (large metropolitan, small metropolitan,
on-metropolitan areas), and health insurance were included
s covariates (Fleury et al., 2014; Wu et al., 2003, 2007).
SDUH deﬁned mutually exclusive racial/ethnic groups based
n respondents’ self-reported race and ethnicity: non-Hispanic
hite, non-Hispanic black, non-Hispanic native-American (Amer-
can Indian/Alaska-native), non-Hispanic native-Hawaiian/Paciﬁc-
slander/Asian-American, mixed-race (>1 race), and Hispanic. We
istinguished among private, public, and no insurance to under-
tand their magnitude of association with treatment use (Dave and
ukerjee, 2011; Wu et al., 2003). We  included a survey year vari-
ble to examine yearly variations in treatment use prevalence.
.2.2. OUD. NSDUH assessments of nonmedical Rx opioid use
ncluded a detailed description of the drug class and a list of
ualifying drugs. Nonmedical use of opioids was deﬁned as any
elf-reported use of Rx pain relievers that was not prescribed for
he respondent, or that the respondent took only for the experi-
nce or feeling they caused. Respondents were read the following
tatement: “These questions are about nonmedical use. We  are
ot interested in your use of ‘over-the-counter’ pain relievers such
s aspirin, Tylenol®, or Advil® that can be bought in drug stores
r grocery stores without a doctor’s prescription.I¨nterviewers also
howed a pill card to the respondents and read the following: “Card
 shows pictures of some different kinds of prescription pain reliev-
rs and lists the names of some others. These pictures show only
ills, but we are interested in your use of any form of Rx pain
elievers that were not prescribed for you or that you took only
or the experience or feeling they caused.R¨espondents who  used
x opioids non-medically in the past year were assessed Rx opioid-
peciﬁc abuse and dependence symptoms in the past year based on
SM-IV criteria (APA, 2000). Respondents who reported heroin use
n the past year were assessed HUD. Consistent with DSM-IV deﬁni-
ion, Rx opioid abuse included presence of ≥1 abuse symptom and
bsence of dependence, and Rx opioid dependence included pres-
nce of ≥3 dependence symptoms (APA, 2000). This sample logic
as applied to deﬁne HUD. We  combined Rx OUD with HUD into
UD (abuse or dependence).
Other behavioral health (need) variables: Like OUD, respon-
ents who reported alcohol or other drug use in the past year
ere then assessed by substance-speciﬁc questions designed to
perationalize DSM-IV criteria for abuse of or dependence on
ach individual substance class (cannabis, cocaine, hallucinogens,
nhalants, stimulants/amphetamines, tranquilizers, or sedatives).
urrent nicotine dependence was assessed by Nicotine Depen-
ence Syndrome Scale (NDSS) and Fagerström Test of Nicotine
ependence (FTND) (Heatherton et al., 1991; Shiffman et al., 2004).
SDUH categorized respondents as having nicotine dependence in
he past month if they met  criteria for dependence as speciﬁed by
ither NDSS or FTND. Due to the association between major depres-
ion and nonmedical opioid use, we examined past-year major
epressive episodes (MDE) as a correlate of treatment use (Wu
t al., 2010). Assessments for MDE  were based on DSM-IV criteria
Kessler and Merikangas, 2004; Kessler et al., 2010).
Substance use treatment: Respondents’ treatment use was
ssessed by separate questions that asked about the receipt of treat-
ent for use of alcohol or drugs and for any drug (e.g., “During
he past 12 months, that is since [DATE FILL] have you received treat-
ent or counseling for your use of alcohol or any drug, not counting
igarettes?”). Among respondents who reported the receipt of treat-endence 169 (2016) 117–127
ment or counseling for drug use, the survey assessed drug-speciﬁc
treatment use during their most recent treatment use. Opioid-
speciﬁc treatment included the receipt of treatment or counseling
for the respondent’s use of Rx opioids or heroin. Among respon-
dents who  reported the receipt of alcohol/drug treatment in the
past year, we examined their treatment locations: hospital (inpa-
tient), alcohol/drug rehabilitation facility (inpatient, outpatient),
mental health facility (outpatient), emergency department, private
doctor’s ofﬁce, self-help group (Alcoholics Anonymous, Narcotics
Anonymous), and prison/jail.
2.3. Data analysis
We  examined racial/ethnic differences in the distributions of
demographics, MDE, and SUDs among adults with OUD. To inform
patient identiﬁcation and intervention, we used descriptive and
logistic regression analyses to characterize differences between Rx
OUD and HUD with respect to respondents’ demographics, MDE,
and SUDs. We calculated prevalence of treatment use (alcohol or
drug, drug, opioid) and location. We conducted logistic regression
to identify factors associated with treatment use. All analyses took
into account the NSDUH’s complex designs (weighting, cluster-
ing; StataCorp, 2013). All results are weighted estimates except for
sample size.
3. Results
3.1. Demographic characteristics of persons with OUD (Table 1)
Among persons with past-year OUD (n = 6,125), three-fourths
met  criteria for DSM-IV opioid dependence. More whites (79.30%)
than blacks (68.90%), native-Hawaiians/Paciﬁc-Islanders/Asian-
Americans (53.81%), and Hispanics (60.76%) had opioid depen-
dence.
A high proportion of persons with OUD were whites (72.29%;
blacks 9.23%, Hispanics 13.82%, others 4.66%), adults aged 18–34
(55.95%), males (57.39%), persons with low income (<$50,000;
67.12%), residents of large metropolitan areas (49.99%), or privately
insured persons (40.97%). Compared with whites, mixed-race
persons and Hispanics included more adolescents, and native-
Americans included a higher proportion of older adults aged
≥50. Among mixed-race persons, there was  a higher pro-
portion of females than males. The vast majority of blacks
(83.78%), native-Americans (88.98%), and Hispanics (76.44%) were
in the lowest income group. A high proportion of blacks,
native-Hawaiians/Paciﬁc-Islanders/Asian-Americans, and Hispan-
ics resided in large metropolitan areas. A high proportion
of native-Americans lived in nonmetropolitan areas. All non-
white groups except for native-Hawaiians/Paciﬁc-Islanders/Asian-
Americans had higher proportions of public insurance than whites.
3.2. Behavioral health indicators (Table 2)
Among persons with OUD, 28.74% had MDE, 53.02% had nico-
tine dependence, 40.93% had alcohol use disorder (AUD), and
43.22% had ≥1 other DUD (cannabis 22.32%, tranquilizer 13.99%,
cocaine 15.25%, stimulant 9.28%, hallucinogen 5.25%, sedative
3.51%, inhalant 2.22%).
Overall, 80.09% of persons with OUD had another SUD (tobacco,
alcohol, drug), which was more prevalent among whites (83.39%)
than Hispanics (72.04%). Nicotine dependence was more common
among whites (57.65%) than Hispanics (36.89%). Compared with
whites, prevalence of MDE  and most SUDs was lower among native-
Hawaiians/Paciﬁc-Islanders/Asian-Americans.
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Table 2
Prevalence of major depressive episode and substance use disorders among persons aged ≥12 years with past-year opioid use disorder: 2005–2013 NSDUH
Race/ethnicity Total White Black Native-American Native-Hawaiian/
Paciﬁc-Islander/
Asian-American***
Mixed-Race Hispanic
Sample size, unweighted n = 6,125 n = 4,361 n = 459 n = 141 n = 99 n = 266 n = 799
Weighted% % (SE) % 95% CI % 95% CI % 95% CI % 95% CI % 95% CI % 95% CI
Major depressive episode†*
Yes 28.74 (1.08) 30.34 27.89–32.91 23.32 16.72–31.54 23.09 13.22–37.17 12.98 5.89–26.24 34.62 22.54–49.06 25.84 20.41–32.13
Other  substance use disorder
(tobacco, alcohol, other
drugs)
Yes 80.09 (0.83) 83.39 81.57–85.07 73.68 66.99–79.43 88.43 72.46–95.69 37.11 20.78–57.04 83.31 73.27–90.09 72.04 64.71–78.36
Alcohol  or other drug use
disorder†
Yes 60.51 (1.01) 61.45 59.13–63.72 56.78 48.46–64.74 74.52 58.12–86.04 33.10 18.39–52.07 64.42 51.08–75.85 60.27 52.48–67.57
Nicotine  dependence‡
Yes 53.02 (1.21) 57.65 54.80–60.45 49.19 40.36–58.06 53.64 33.97–72.23 14.45 6.26–29.93 50.90 38.62–63.07 36.89 29.69–44.71
Alcohol  use disorder†
Yes 40.93 (0.98) 41.17 39.00–43.39 35.01 28.01–42.73 54.89 39.05–69.80 19.35 8.68–37.74 43.26 32.53–54.65 45.11 38.14–52.27
Other  drug use disorder†**
Yes 43.22 (1.01) 43.38 41.13–45.67 43.65 35.93–51.70 47.50 30.70–64.89 18.38 9.77–31.89 53.06 39.82–65.88 44.09 36.58–51.89
Cannabis  use disorder†
Yes 22.32 (0.70) 21.76 20.23–23.39 17.33 12.83–22.99 30.82 16.39–50.30 11.45 5.32–22.96 27.32 19.90–36.26 28.76 22.81–35.55
Tranquilizer use disorder†
Yes 13.99 (0.70) 14.54 13.10–16.10 13.70 8.37–21.61 15.54 7.09−30.72 2.91 0.95–8.60 12.26 8.18–17.96 12.92 8.04–20.11
Cocaine  use disorder†
Yes 15.25 (0.94) 14.49 12.76–16.40 21.46 14.90–29.89 10.01 4.83–19.60 2.21 0.69–6.87 20.31 9.52–38.17 16.79 11.79–23.35
Stimulant  use disorder†
Yes 9.28 (0.80) 9.79 8.24–11.61 8.67 3.74–18.83 6.72 2.81–15.20 3.44 1.24–9.20 8.24 5.62–11.92 8.11 4.45–14.34
Hallucinogen use disorder†
Yes 5.25 (0.38) 4.78 4.06–5.60 6.26 3.88–9.94 3.81 1.42–9.84 0.87 0.16–4.45 8.52 4.85–14.54 7.46 4.68–11.70
Sedative  use disorder†
Yes 3.51 (0.43) 3.24 2.43–4.32 4.40 2.12–8.91 11.33 3.88–28.81 2.77 0.83–8.90 3.10 1.80–5.29 3.77 1.56–8.82
Inhalant  use disorder†
Yes 2.22 (0.22) 1.96 1.52–2.53 2.06 1.05–3.99 2.83 1.11–7.03 4.77 1.51–14.03 3.51 1.67–7.21 3.14 1.93–5.08
†  In the past year. ‡  In the past month. *The sample was  5,977 (148 respondents with missing data on major depressive episode were excluded). **Other drug included cannabis, tranquilizer, cocaine, stimulant, hallucinogen,
sedative, or inhalant use disorder. SE: standard error; CI: conﬁdence interval. ***Estimates are preliminary due to sample size. Boldfaced: The estimate in that group differed from the estimate among whites (P < 0.05).
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Table 3
Adjusted odds ratios (AORs) of Rx opioid and heroin use disorders among persons aged ≥12 years with past-year opioid use disorder (n = 5,977*).
Rx opioid use disorder (Rx OUD)
and heroin use disorder (HUD)
Rx OUD only HUD only Rx OUD+ HUD Rx OUD + HUD vs. Rx OUD only†  HUD only vs. Rx OUD  only†
Weighted% Row, % Row, % Row, % AOR 95% CI AOR 95% CI
Total  81.93 9.75 8.32
Race/ethnicity
White 82.55 7.81 9.64 1.00 1.00
Black  76.49 18.20 5.32 0.63 0.26–1.54 2.24 1.44–3.47
Native-American 93.69 4.75 1.57 0.15 0.03–0.72 0.54 0.15–2.02
Native-Hawaiian/Paciﬁc-
Islander/Asian-American
96.45 0.40 3.15 0.47 0.10–2.15 0.06 0.01–0.26
Mixed-race 79.05 13.51 7.44 0.94 0.38–2.34 2.39 0.81–7.04
Hispanic 79.75 15.48 4.77 0.53 0.30–0.93 2.04 1.20–3.44
Age  in years
12–17 94.00 3.14 2.85 1.00 1.00
18–25 81.03 9.25 9.72 2.62 1.67–4.11 2.85 1.77–4.60
26–34  79.86 11.15 8.98 2.00 1.17–3.44 2.73 1.52–4.90
35–49  80.26 10.30 9.44 2.97 1.67–5.27 2.59 1.55–4.32
50+  79.81 13.69 6.49 1.85 0.77–4.43 3.10 1.45–6.64
Sex
Male  78.50 10.79 10.70 1.00 1.00
Female 86.54 8.35 5.12 0.44 0.32–0.60 0.75 0.55–1.02
Total  annual family income
<$50,000 80.38 11.03 8.59 1.00 1.00
$50,000–$74,999 86.76 6.85 6.40 0.80 0.46–1.39 0.81 0.52–1.25
$75,000+ 83.87 7.37 8.76 1.05 0.73–1.51 0.88 0.56–1.40
Population density
Large metropolitan 76.14 14.18 9.68 1.00 1.00
Small  metropolitan 86.97 5.67 7.36 0.57 0.37–0.87 0.32 0.23–0.45
Nonmetropolitan 93.09 2.85 4.07 0.30 0.14–0.67 0.13 0.06–0.28
Health insurance
None 76.07 12.53 11.40 1.00 1.00
Private 86.85 6.16 6.99 0.67 0.47–0.95 0.57 0.40–0.81
Public 80.97 12.02 7.01 0.71 0.42–1.18 0.89 0.59–1.35
Major  depressive episode-past
year
No 81.42 10.74 7.84 1.00 1.00
Yes  83.17 7.31 9.53 1.04 0.69–1.57 0.62 0.44–0.87
Nicotine dependence-current
No 89.31 5.68 5.01 1.00 1.00
Yes  75.34 13.38 11.27 2.15 1.48–3.12 2.59 1.77–3.80
Alcohol use disorder-past year
No 80.86 11.13 8.01 1.00 1.00
Yes  83.46 7.77 8.78 0.85 0.58–1.26 0.57 0.41–0.81
Other  drug use disorder-past
year**
No 86.74 8.52 4.74 1.00 1.00
Yes  75.61 11.37 13.02 3.37 2.20–5.17 1.80 1.28–2.53
Year
2005  87.24 7.81 4.95 1.00 1.00
2006  84.00 12.02 3.99 0.87 0.32–2.38 1.32 0.64–2.70
2007  88.49 6.08 5.44 1.01 0.36–2.80 0.64 0.34–1.21
2008  84.50 10.21 5.29 0.98 0.39–2.48 1.10 0.59–2.03
2009  79.99 13.20 6.81 1.44 0.71–2.91 1.76 0.93–3.34
2010  82.23 8.46 9.31 1.88 0.92–3.83 0.98 0.51–1.90
2011  77.71 11.74 10.55 2.26 1.06–4.82 1.50 0.79–2.87
2012  79.20 9.36 11.44 2.38 1.19–4.76 1.01 0.56–1.84
2013  76.50 8.55 14.95 3.13 1.60–6.10 0.93 0.52–1.67
*The sample was  5,977 (148 respondents with missing data on major depressive episode were excluded). **Other drug included cannabis, tranquilizer, cocaine, stimulant,
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.3. Differences between HUD and Rx OUD among persons with
UD (Table 3)
Among persons with past-year OUD, 81.93% had Rx OUD only,
.75% had HUD only, and 8.32% had Rx OUD + HUD. Adjusted logistic
egression indicated that white race (vs. native-American, His-
anic), ages 18–49 (vs. ages 12–17), male sex (vs. female), large
etropolitan areas (vs. small or non-metropolitan), no insurance
vs. private insurance), nicotine dependence, and other DUD were
ssociated with increased odds of having Rx OUD + HUD vs. Rx OUD
nly. The proportion of persons with Rx OUD + HUD increased ind all variables listed in the ﬁrst column. CI: conﬁdence interval. AOR: adjusted odds
2011–2013 (vs. 2005). Blacks or Hispanics (vs. whites), adults (vs.
adolescents), residents in large metropolitan areas, the uninsured
(vs. privately insured), person with nicotine dependence or other
DUD, and persons without MDE  or AUD had elevated odds of having
HUD only vs. Rx OUD only.
3.4. Substance use treatment and settings (Table 4, Fig. 1a–b)Among persons with OUD, 26.19% used alcohol or drug use
treatment, 23.07% used any drug use treatment, and 19.44% used
opioid-speciﬁc treatment. Prevalence of treatment use was  higher
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Table 4
Prevalence of treatment use among persons aged ≥12 years with past-year opioid use disorder: 2005–2013 NSDUH.
Race/ethnicity Total White Black Native-American Native-Hawaiian/
Paciﬁc-Islander/
Asian-American‡
Mixed-Race Hispanic
Past-year treatment
service use,
weighted%
% 95% CI % 95% CI % 95% CI % 95% CI % 95% CI % 95% CI % 95% CI
Alcohol/drug use related service use-past year,%
Persons with opioid
abuse (n = 1,654)
12.96 10.30–16.17 14.61 10.97–19.21 14.49 6.85–28.06 22.74 8.42–48.51 5.39 1.44–18.19 9.53 3.28–24.66 8.54 4.93–14.40
Persons  with opioid
dependence
(n = 4,471)
30.54 27.95–33.26 30.21 27.59–32.96 31.89 22.94–42.42 29.66 15.26–49.67 4.50 1.41–13.42 35.87 21.32–53.58 34.33 25.55–44.35
Persons  with opioid
abuse/dependence
(n = 6,125)
26.19 24.00–28.51 26.98 24.68–29.40 26.48 19.64–34.67 28.15 17.15–42.58 4.91 2.09–11.12 30.46 18.31–46.13 24.21 18.63–30.84
Drug  use related service use-past year, %
Persons with opioid
abuse (n = 1,654)
10.91 8.42–14.01 12.86 9.41–17.34 9.68 4.24–20.61 20.31 7.01–46.29 4.59 1.04–18.09 8.70 2.88–23.41 6.87 3.53–12.95
Persons  with opioid
dependence
(n = 4,471)
27.07 24.48–29.82 27.36 24.72–30.16 23.09 15.95–32.22 26.77 13.07–47.05 4.50 1.41–13.42 35.12 20.59–53.06 29.75 21.01–40.28
Persons  with opioid
abuse/dependence
(n = 6,125)
23.07 20.90–25.40 24.36 22.04–26.83 18.92 13.62–25.68 25.36 14.79–39.95 4.54 1.84–10.80 29.70 17.60–45.53 20.77 15.16–27.79
Opioid  use related service use-past year, %
Persons with opioid
abuse (n = 1,654)
5.07 3.68–6.94 5.55 3.58–8.52 7.62 2.88–18.70 7.74 1.92–26.47 0 . . ..  . . 3.81 1.13–12.11 3.18 1.42–6.98
Persons  with opioid
dependence
(n = 4,471)
24.16 21.89–26.59 24.69 22.18–27.38 19.29 13.02–27.61 25.88 12.37–46.36 2.30 0.69–7.33 27.87 13.99–47.85 26.23 17.85–36.79
Persons  with opioid
abuse/dependence
(n = 6,125)
19.44 17.63–21.40 20.73 18.63–23.00 15.66 10.89–21.99 21.93 12.00–36.65 1.24 0.39–3.87 22.94 11.56–40.39 17.19 11.96–24.08
Location  of services received among past-year alcohol/drug use treatment users, % (n=1,487)
Self-help group 59.42 55.10–63.59 57.10 52.64–61.45 70.28 57.55–80.50 83.78 63.01–94.00 79.10 39.99–95.56 73.36 49.94–88.37 60.00 42.80–75.05
Rehabilitation,
outpatient
53.93  49.83–57.97 52.74 48.13–57.32 71.26 58.13–81.58 62.13 35.07–83.29 46.44 14.07–82.11 64.11 36.78–84.57 46.15 29.84–63.32
Rehabilitation,
inpatient
45.23  41.06–49.47 45.73 40.74–50.81 55.07 40.83k68.52 52.86 26.48–77.73 46.47 14.20–81.98 13.13 5.33–28.87 38.75 25.22–54.26
Hospital,  inpatient 40.12 35.94–44.46 39.02 34.50-43.74 46.05 31.59–61.20 50.78 24.49–76.64 20.22 4.45–57.95 55.00 27.58–79.68 39.65 24.95–56.49
Mental  health center,
outpatient
35.75 31.59–40.14 36.50 31.93–41.32 29.87 17.36–46.34 60.48 34.93–81.36 45.32 13.44–81.57 49.57 21.75–77.66 30.99 19.85–44.89
Private  doctor’s ofﬁce 30.14 25.52–35.19 31.21 26.43–36.44 20.30 10.59–35.38 16.77 4.89–44.10 60.49 22.47–89.00 26.24 8.09-58.96 32.07 18.63-49.34
Emergency department 27.40 23.39–31.81 25.76 21.48–30.56 36.09 20.75–54.92 31.05 8.61–68.29 30.58 6.22–74.55 54.58 26.75–79.82 26.42 13.54–45.16
Prison/jail 13.69 10.84–17.13 12.05 9.12–15.75 15.96 7.51–30.78 14.60 4.65–37.46 48.81 15.15–83.58 8.09 2.66–22.07 21.27 10.69–37.87
CI: conﬁdence interval. Opioid use disorder included Rx opioid or heroin use disorder in the past year. ‡  Estimates are preliminary due to sample size.
Boldfaced: The estimate in that group differed from the estimate among whites (P < 0.05).
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dig. 1. (a) Prevalence of alcohol or drug use treatment use among persons aged ≥12
ettings  among persons aged ≥12 years with opioid use disorder that received alco
mong persons with opioid dependence (alcohol/drug 30.54%,
ny drug 27.07%, opioid 24.16%) than persons with opioid abuse
alcohol/drug 12.96%, any drug 10.91%, opioid 5.07%). Naive-
awaiians/Paciﬁc-Islanders/Asian-Americans with OUD had the
owest prevalence of treatment use (alcohol/drug 4.91%, any drug
.54%, opioid 1.24%).
Among alcohol/drug use treatment users, common settings
ere self-help groups (59.42%), outpatient rehabilitation units
53.93%), inpatient rehabilitation units (45.23%), inpatient hospitals
40.12%), and outpatient mental health facilities (35.75%). A higher
roportion of Native-Americans (83.78%) than whites (57.10%)
sed self-help groups. More blacks (71.26%) than whites (52.74%)
sed outpatient rehabilitation. Fewer mixed-race persons (13.13%)
han whites (45.73%) used inpatient rehabilitation programs.
.5. Adjusted odds ratio of substance use treatment (Table 5)
Among persons with OUD, we conducted adjusted logistic
egression to estimate correlates of alcohol/drug use treatment
se, drug use treatment, and opioid-speciﬁc treatment use, respec-
ively. Compared with whites, blacks had lower odds of using
rug use and opioid-speciﬁc treatment; native-Hawaiians/Paciﬁc- with past-year opioid use disorder: 2005–2013 NSDUH (n = 6,125). (b). Treatment
 drug use treatment in the past year: 2005–2013 NSDUH (n = 1,487).
Islanders/Asian-Americans had lower odds of using treatment for
alcohol/drug use and opioid-speciﬁc treatment. Other correlates
of treatment use were generally similar for alcohol/drug use, any
drug use, and opioid-speciﬁc treatment. Ages 12–17 (vs. ages 18 + )
and no insurance (vs. public insurance) were associated with lower
odds of using opioid-speciﬁc treatment. Having HUD, MDE, nico-
tine dependence, or other DUD was associated with increased odds
of using opioid-speciﬁc treatment. Finally, compared with treat-
ment use in 2005, the odds of treatment use for alcohol, drug, or
opioid use problems increased in 2012, which was  consistent with
descriptive results (Table S1).
4. Discussion
In the United States, there has been a continuous 15-year
upward trend in opioid overdose deaths (Rudd et al., 2016). Based
on drug overdose death data between 1980 and 2011, Darakjy
et al. (2014) estimated that drug overdose mortality rates would
reach its peak in 2016–2017 and take about 18 years (by 2034)
to return to the 1980 baseline level. These estimates demonstrate
a need for active efforts to improve access to OUD  treatment
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Table  5
Adjusted analysis of past-year treatment service use among persons aged ≥12 years with past-year opioid use disorder: 2005–2013 NSDUH (n = 5,977a).
Treatment type Alcohol/drug use treatment
service use†
Drug use treatment service
use†
Opioid use treatment service
use†
Adjusted odds ratio, AOR AOR 95% CI AOR 95% CI AOR 95% CI
Race/ethnicity (vs. white)
Black 0.73 0.47–1.14 0.50 0.31–0.80 0.47 0.29–0.77
Native-American 1.14 0.56–2.32 1.16 0.55–2.45 1.32 0.57–3.05
Native-Hawaiian/Paciﬁc-Islander/Asian-American 0.23 0.08–0.64 0.22 0.08–0.67 0.09 0.03–0.31
Mixed-race 0.98 0.52–1.85 1.09 0.56–2.16 0.91 0.42–1.98
Hispanic 0.81 0.55–1.20 0.75 0.49–1.14 0.79 0.48–1.30
Age  in years (vs. 12–17)
18–25 1.19 0.95–1.51 1.26 1.00–1.60 1.80 1.45–2.25
26–34 1.19 0.86–1.64 1.20 0.87–1.65 1.72 1.26–2.36
35–49 1.74 1.21–2.50 1.96 1.34–2.86 2.65 1.78–3.94
50+  1.33 0.70–2.50 1.27 0.63–2.56 2.34 1.19–4.60
Sex  (female vs. male) 1.03 0.81–1.31 1.04 0.80–1.36 1.30 0.96–1.76
Total  annual family income (vs. <$50,000)
$50,000–$74,999 0.82 0.60–1.14 0.83 0.59–1.18 0.68 0.46–1.02
$75,000+ 1.11 0.81–1.53 1.16 0.85–1.57 1.10 0.79–1.54
Population density (vs. large metropolitan)
Small metropolitan 0.74 0.59–0.94 0.79 0.62–1.00 0.80 0.61–1.05
Nonmetropolitan 1.02 0.59–1.78 1.16 0.66–2.04 1.15 0.64–2.06
Health insurance (vs. none)
Private 1.31 0.97–1.75 1.23 0.93–1.64 1.29 0.95–1.76
Public 1.89 1.42–2.52 1.86 1.41–2.45 1.57 1.17–2.10
Heroin use disorder (yes vs. no) 5.12 4.12–6.37 5.20 4.10–6.59 6.23 4.78–8.12
Major depressive episode – past year (yes vs. no) 1.58 1.21–2.06 1.51 1.16–1.98 1.40 1.04–1.89
Nicotine dependence – current (yes vs. no) 1.96 1.54–2.49 1.80 1.40–2.31 1.78 1.32–2.39
Alcohol use disorder – past year (yes vs. no) 1.15 0.92–1.44 0.93 0.75–1.16 0.78 0.63–0.98
Other drug use disorder-past yearb (yes vs. no) 2.00 1.54–2.61 2.17 1.70–2.79 1.84 1.39–2.45
Year  (vs. 2005)
2006 1.45 0.91–2.31 1.55 0.93–2.56 1.25 0.74–2.12
2007 1.40 0.84–2.33 1.00 0.60–1.67 1.11 0.65–1.89
2008 1.03 0.66–1.62 0.99 0.63–1.56 1.02 0.62–1.69
2009 1.28 0.86–1.89 1.14 0.73–1.79 1.25 0.79–2.00
2010 1.29 0.83–2.00 1.04 0.66–1.62 0.88 0.55–1.42
2011  1.63 1.07–2.48 1.53 0.97–2.42 1.51 0.95–2.39
2012  1.59 1.10–2.32 1.56 1.06–2.30 1.67 1.11–2.50
2013  1.22 0.74–2.00 1.13 0.66–1.93 1.20 0.72–2.01
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b Other drug included illicit drugs other than opioid and heroin. †Each adjusted l
OR:  adjusted odds ratio. Boldfaced: P < 0.05.
or all racial/ethnic groups. These ﬁndings from a large sample
ave implications for informing federal initiatives for expanding
AT  to reduce opioid addiction. First, opioid overdose mortality
ata do not directly measure OUD-a common indicator for treat-
ent. This study adds new estimates drawn from a large sample
n = 503,101) to understand patterns of Rx OUD and HUD and iden-
ify treatment gaps for demographic groups. Additionally, there
re mounting concerns about heroin use-related conditions, such
s injection drug use and HIV/hepatitis virus infections (Conrad
t al., 2015; Zibbell et al., 2015). This analysis adds unique infor-
ation about the extent and some proﬁles of Rx OUD + HUD and
UD only. Persons with HUD represented 18% of persons with OUD
10% HUD only, 8% Rx OUD + HUD). Consistent with heroin-involved
eath data (Compton et al., 2016), we found that proportions of Rx
UD + HUD among persons with OUD tripled between 2005 (4.95%)
nd 2013 (14.95%). Our data further revealed that persons with Rx
UD + HUD tended to be white, male, aged 18–49, or uninsured,
hich is useful information for targeting demographic characteris-
ics of opioid users to address overdose prevention. Because people
ith Rx OUD + HUD are likely to have severe comorbidities (Wu
t al., 2011b), results suggest a rising demand for MAT  to man-
ge increased numbers of persons with complex Rx OUD + HUD.
iven heroin’s elevated purity levels and rising use rates (DEA,
015), in-depth research that can elucidate contextual and risk
actors for initiating heroin use is needed to guide prevention
trategies (Pollini et al., 2011). The high rate of injection drug use
mong heroin users and increased heroin use among whites and the
ninsured (Rudd et al., 2016; SAMHSA, 2014) suggest urgency inde were excluded).
 regression included all variables listed in the ﬁrst column. CI: conﬁdence interval.
identifying effective OUD care models to facilitate treatment entry
and care coordination.
Another salient ﬁnding concerns low treatment use and severe
patterns of OUD and comorbidity: 75% of persons with OUD had
opioid dependence, 80% had another SUD, and 29% had MDE. On
average, more whites than blacks or Hispanics had opioid depen-
dence or another SUD. Whites represented 72% of persons with
OUD. The burden of OUD has disproportionally affected whites,
especially those with low-income or living in rural areas where
MAT resources are especially limited (Hansen et al., 2011; Jones
et al., 2015a,b). Despite the high prevalence of comorbid SUD, just
26% of persons with OUD received ‘any’ alcohol/drug use treatment,
and 19% used opioid-speciﬁc treatment. Thus, even in a subset of
persons with ≥1 SUD that made the contact with SUD services,
approximately one-fourth of treatment users might have their OUD
unaddressed. Given its comorbidity, strategies for enhancing OUD
treatment could improve detection of OUD among persons who
already are in treatment for SUD or mental health conditions to
facilitate treatment engagement. Additionally, as most people with
OUD have not accessed OUD care, multifaceted interventions are
required to change macro-environmental attitudes and knowl-
edge towards OUD and treatment (e.g., misperceptions, stigma) in
order to develop a more supportive culture and infrastructure to
enable treatment-seeking for OUD (DeFlavio et al., 2015; Saloner
and Karthikeyan, 2015; Volkow and McLellan, 2016).
The low rates of treatment reinforce the urgency of expand-
ing insurance coverage by implementing the Affordable Care Act
(ACA) and developing the infrastructure and workforce that can
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acilitate delivery of preventive and treatment services to address
he opioid epidemic (Andrews et al., 2015). Unlike other medi-
al illnesses, public funding provides crucial support for addiction
reatment, while uninsurance or under-insurance are signiﬁcant
arriers to SUD care (Ali and Mutter, 2016). Further, treatment for
UD requires coverage for an extended period of treatment to facil-
tate recovery. We  found that public insurance was  an enabling
orrelate of treatment use, while private insurance did not differ
rom no insurance in predicting treatment use (Wu et al., 2003,
011c). Unfortunately, most states have failed to use ACA resources
dequately to help expand addiction treatment (Andrews et al.,
015). Uninsured adults are disproportionally affected by OUD. ACA
as important implications for improving population health.
Adolescents, the uninsured, blacks, and native-
awaiians/Paciﬁc-Islanders/Asian-Americans particularly
nderutilized opioid-speciﬁc treatment. Data from adoles-
ents with OUD showed a very low rate of treatment use among
lacks (<4%), and adolescents with OUD were unlikely to use
reatment unless they were involved with the criminal justice
ystem (Wu  et al., 2011c). Adolescent-onset OUD suggested a high
isk for severe OUD; as a result, comorbidity could have a lasting
egative impact (Chambers et al., 2003; Wu et al., 2008, 2010).
he low treatment use may  be related to inadequate MAT  data for
dolescents. Clinical trials are needed to inform treatment options
or adolescents with OUD (Fishman et al., 2010; Matson et al.,
014). Native-Hawaiians/Paciﬁc-Islanders/Asian-Americans with
UD had the lowest prevalence of using alcohol/drug treatment
4.91%) or opioid-speciﬁc treatment (1.24%). Cultural-related
tigma toward addiction and a lack of culturally congruent addic-
ion providers are unique barriers to seeking treatment among
ative-Hawaiians/Paciﬁc-Islanders/Asian-Americans (Wu  and
lazer, 2015). Finally, residents in rural areas have relatively high
ates of opioid overdoses, but they face substantial barriers to OUD
reatment (e.g., shortage of mental/behavioral health providers;
DC, 2012; Quest et al., 2012). We  found that persons who lived in
mall or non-metropolitan areas were likely to have Rx OUD only,
uggesting that expansions of ofﬁce-based OUD treatment will be
ritical to improving OUD care (Stein et al., 2012).
This study has limitations. All results were based on self-reports.
he cross-sectional data preclude causal interpretation. NSDUH
xcludes the homeless, military personnel on active duty, and resi-
ents of institutional group quarters. The survey does not collect
he quality of addiction or opioid-speciﬁc care. Because treat-
ent use is deﬁned broadly to include any treatment service, the
reatment gap is likely greater than these estimates. The results
or native-Hawaiians/Paciﬁc-Islanders/Asian-Americans with OUD
re limited by a small sample size and should be considered
reliminary. However, Native-Hawaiians/Paciﬁc-Islanders/Asian-
mericans are the fastest growing segments of the US population,
nd their addiction treatment needs are vastly under-recognized
Wu and Blazer, 2015). Their very low prevalence of opioid-speciﬁc
reatment use (1.2%) merits research to identify effective strategies
o combat opioid misuse/addiction. The NSDUH also has strengths.
t is the primary source for estimating persons with OUD and treat-
ent use, and it includes a large sample to identify underserved
roups. For example, the NESARC–III (n = 36,309) included a small
umber (n = 330) of adults with past-year Rx OUD (Saha et al.,
016).
In conclusion, annual economic costs of nonmedical opioid
se/Rx OUD were $53.4 billion in 2006 (Hansen et al., 2011); annual
ost estimates for heroin use were $21.9 billion in 1996 (Mark et al.,
001). The low rate of OUD treatment use coupled with increases
n heroin-involved deaths indicate escalating societal costs that
an be intensiﬁed by untreated OUD. The huge economic burden
f these largely untreated disorders highlights the importance of
nvestment in education, research, prevention, and treatment forendence 169 (2016) 117–127
OUD. The ACA and federal opioid initiatives provide opportunities
to transform the delivery of SUD care and curb the opioid overdose
trajectories.
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